Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

단계 해당 없음 완료 NCT04972929

대상 질환	Multiple Sclerosis, Relapsing-Remitting
임상 단계	단계 해당 없음
스폰서	University of Alabama at Birmingham
상태	완료
참여자 수	26 명
중재(약물)	Spinal Manipulation, Sham Spinal Manipulation
시작일	2023년 9월 15일
완료일	2025년 3월 12일
결과 공개일	2026년 7월 20일

요약

Multiple sclerosis (MS) is an inflammatory autoimmune disease associated with an imbalance between pro- and anti-inflammatory markers (cytokines) resulting in a demyelinating and neurodegenerative disease. There is early evidence that spinal manipulation (chiropractic care) is better than control in influencing immune (cytokine) activity in asymptomatic participants, but few studies have been completed in participants with chronic inflammatory conditions, such as MS. The purpose of this project is to examine the immediate (after a single thoracic spinal manipulation treatment) and summative impact (after 8 thoracic spinal manipulation treatments occurring over 4 weeks) on pro-inflammatory (interleukin (IL) IL-1ß, IL-2, IL-6, Tumor necrosis factor-alpha) and anti-inflammatory (IL-4, IL-10) plasma cytokines 20 minutes and 2 hours after thoracic spinal manipulation in participants diagnosed with neuroinflammatory relapsing-remitting MS (RR-MS). Spinal manipulation treatment will be limited to the thoracic spine. Secondary outcomes will include determining the impact of 8 thoracic spinal manipulations on fatigue, cognitive processing speed, pain, depression, sleep, and motor function t

IL-6 Serum Inflammatory Cytokine Levels

From baseline to after 8th treatment at 4 weeks · pg/mL

Spinal Manipulation/Trigger Point Therapy	3.85 ± 6.01 pg/mL
Sham-spinal Manipulation	2.76 ± 4.77 pg/mL

Mean Difference (Final Values)	-0.24 (95% CI -0.78–0.30)

IL-4 Serum Inflammatory Cytokine Levels

From baseline to after 8th treatment at 4 weeks · pg/ML

Thoracic Spinal Manipulation/Trigger Point Therapy	83.85 ± 187.51 pg/ML
Sham-spinal Manipulation Group	73.36 ± 198.60 pg/ML

Mean Difference (Final Values)	-0.03 (95% CI -4.69–4.62)

IL-10 Serum Inflammatory Cytokine Levels

From baseline to after 8th treatment at 4 weeks · pg/ML

Thoracic Spinal Manipulation/Trigger Point Therapy	12.01 ± 25.01 pg/ML
Sham-manipulation Group	8.82 ± 17.14 pg/ML

Mean Difference (Final Values)	0.15 (95% CI -1.32–1.85)

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of — Mapi Pharma Ltd.
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patient — Genzyme, a Sanofi Company
A Study of Oxidative Pathways in MS Fatigue — University of California, San Francisco
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Bioma — Gregory Wu
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocr — Hoffmann-La Roche

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.

English 한국어 日本語中文 Русский